Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome

Minerva Endocrinologica

Volumn 39, Issue 2, 2014, Pages 99-105

  Karbek, B ^a   Bozkurt, N C ^a   Topaloglu, O ^a   Aslan, M S ^a   Gungunes, A ^a   Cakal, E ^a   Delibasi, T ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

C reactive protein ; Insulin resistance; Metabolic syndrome X

Indexed keywords

ADIPOCYTOKINE; APELIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VASPIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; SMOKING; WAIST HIP RATIO;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 84904115568     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ebbeling CB, Pawlak DB, Ludwig DS. Childhood obesity: public-health crisis, common sense cure. Lancet 2002;360:473-82. (Pubitemid 34880150)
2. Sen Y, Kandemir N, Alikasifoglu A, Gonc N, Ozon A. Prevalence and risk factors of metabolic syndrome in obese children and adolescents: the role of the severity of obesity. Eur J Pediatr 2008;167:1183-9.
3. Erem C, Hacihasanoglu A, Deger O, Topbaş M, Hosver I, Ersoz HO et al. Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study. Endocrine 2008;33:9-20.
4. Cizmecioglu FM, Etiler N, Hamzaoglu O, Hatun S. Prevalence of metabolic syndrome in schoolchildren and adolescents in Turkey: a population-based study. J Pediatr Endocrinol Metab. 2009;22:703-14.
5. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-801. (Pubitemid 44033299)
6. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005;19:547-66. (Pubitemid 41823815)
7. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-5. (Pubitemid 41061602)
8. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008;17:327-33. (Pubitemid 351578185)
9. Youn BS, Klöting N, Kratzsch J, Lee N, Park JW, Song ES et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-7.
10. Seeger J, Ziegelmeier M, Bachmann A, Lössner U, Kratzsch J, Blüher M et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008;93:247-51.
11. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Klöting N et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009;204:262-6.
12. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 2011;412:48-52.
13. Gulcelik NE, Karakaya J, Gedik A, etal. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009;160:65-70.
14. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005;107:198-211. (Pubitemid 40916219)
15. Rayalam S, Della-Fera MA, Krieg PA, Cox CM, Robins A, Baile CA. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun 2008;368:815-9.
16. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275:21061-7. (Pubitemid 30481796)
17. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538:162-71. (Pubitemid 32402239)
18. Sörhede Winzell M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005;131:12-7.
19. Ringström C, Nitert MD, Bennet H, Fex M, Valet P, Rehfeld JF et al. Apelin is a novel islet peptide. Regul Pept 2010;162:44-51.
20. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-73. (Pubitemid 37088727)
21. Peterson MC. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit 2005;11:229-32.
22. Kralisch S, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem 2007;7:39-45. (Pubitemid 46062372)
23. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Nad Acad Sci USA 2005;102:10610-5. (Pubitemid 41061602)
24. Senolt L, Polanská M, Filková M, Cerezo LA, Pavelka K, Gay S et al. Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 2010;69:1410-1.
25. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb 2010;17:115-30.
26. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A et al. Apelin, a newly identified adipokine upregulated by insulin and obesity. Endocrinology 2005;146:1764-71. (Pubitemid 40396885)
27. Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 2010;298:1161-9.
28. Yue P, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 2010;298:59-67.
29. Rittig K, Hildebrandt U, Thamer C, Staiger H, Peter A, Stefan N et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes, 2011;119:358-61.
30. Tapan S, Tascilar E, Abaci A. Decreased plasma apelin levels in pubertal obese children. J Pediatr Endocrinol Metab 2010;23:1039-46.